Guillermo Villacampa, Head of Statistics Unit at Vall d´Hebron Institute of Oncology (VHIO), shared a post on LinkedIn about a paper he co-authored with colleagues published in Cancer Treatment Reviews:
” ‘Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of HR+ advanced breast cancer’ published in Cancer Treatment Reviews. Great thanks to Alicia Escudero and Tomás Pascual Martínez for their thorough work, proactiveness, and commitment.
Question: What is the best treatment strategy after progression on CDK4/6i?
Previous evidence: Several strategies have emerged in this post-CDK4/6i setting: i) SERDs/SERMs/PROTACs, ii) inhibitors of the PI3K/AKT/mTOR pathway, or iii) continuation or rechallenge with CDK4/6i in. However, the multiple potential combinations and the lack of direct head-to-head comparisons constrain evidence-based treatment sequencing.
Study Design: A network meta-analysis was conducted based on 20 RCTs involving 4,716 patients with HR+/HER2- tumours to integrate the existing evidence. Additionally, an extracted individual patient data meta-analysis was conducted. Results are presented independently in tumours with PI3K-AKT-PTEN alterations, ESR1-mutated and wild-type tumours.”
Title: Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor-positive advanced breast cancer: A systematic review and network meta-analysis
Authors: Alicia Escudero, Meritxell Bellet, Cristina Saura, Anna Aguilera, Andri Papakonstantinou, Pablo Tolosa, José Ángel García-Sáenz, Fernando Moreno, Alfonso López de Sá, Francesco Schettini, Elia Seguí, Marta Gonzalez-Rodríguez, Víctor Navarro, Juan Manuel Ferrero-Cafiero, Xavier González, Cristina Hernando, Alexios Matikas, Aleix Prat, Mafalda Oliveira, Tomas Pascual, and Guillermo Villacampa
You can read the Full Article in Cancer Treatment Reviews.
More posts featuring Guillermo Villacampa.
